VPB0611 - Alteration of circulating ACE2 regulating microRNAs profiles in patients with COVID-19

Monday, July 11, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: Virtual

Co-Author(s)

Zofia Wicik, PhD

Senior Researcher
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, 02-091 Warsaw, Poland
Warsaw, Mazowieckie, Poland

Presenting Author(s)

CE

Ceren Eyileten

Senior Researcher
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology CEPT, 02-091 Warsaw, Poland
Warsaw, Mazowieckie, Poland

Co-Author(s)

JJ

Joanna Jarosz-Popek

PhD candidate
Medical University of Warsaw
Warsaw, Mazowieckie, Poland
DJ

Daniel Jakubik

PhD candidate
Medical University of Warsaw
Warsaw, Mazowieckie, Poland
AN

Anna Nowak

PhD candidate
Medical University of Warsaw
Warsaw, Mazowieckie, Poland
MW

Marta Wolska

PhD candidate
Medical University of Warsaw
warsaw, Mazowieckie, Poland
AS

Andleeb Shahzadi

Assistant Prof
Istanbul Cerrahpasa University
Istanbul, Istanbul, Turkey
DM

David Martins-Jr

Dr
Federal University of ABC
Sao Paulo, Sao Paulo, Brazil
SS

Sérgio Simões

Dr
Federal Institute of Espírito Santo
Sao Paulo, Sao Paulo, Brazil
JS

Jolanta M. Siller-Matula

Professor
Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna,1090 Vienna, Austria
Vienna, Wien, Austria
MP

Marek Postula

Prof
Medical University of Warsaw
Warsaw, Mazowieckie, Poland

Background: SARS-CoV-2 tropism for the ACE2 receptor, along with the multifaceted inflammatory reaction, is likely to drive the generalized hypercoagulable state seen in patients with COVID-19.

Aims: According to our previously published bioinformatics analysis, we aimed to analyze the diagnostic and predictive utility of miRNAs regulating ACE2 network (miR-26b-5p, miR-10b-5p, miR-302c-5p, hsa-miR-200b-3p, hsa-miR-124-3p) in patients with COVID-19

Methods: We determined the expressions of ACE2-related-miRNAs in 79 hospitalized COVID-19 patients and 32 healthy volunteers by PCR and monitored miRNAs patterns during the acute phase of COVID-19, as well as the prognostic potential of these miRNAs as biomarkers.

Results: The expression levels of miR-26b-5p in COVID-19 patients were found lower at the baseline, 7 and 21-days after admission. compared to the healthy controls (p < 0.0001 for all time points). Similarly, miR-10b-5p expression levels were lower at the baseline and 21-days post admission in COVID-19 patients when compared to the healthy individuals (p=0.001 in both time points). Moreover, expression levels of this miRNA were higher 7-days post-admission when compared to the baseline (p=0.003). According to the ROC curve analysis, low miR-200b-3p expression presents predictive utility in assessment of the hospital length of stay and/or death (AUC:0.730, p=0.002). According to the multivariable logistic regression model, low delta miR-200p expression, together with diabetes mellitus (DM), are independent predictors of increased hospital length of stay and/or death (OR: 5.775; 95% CI, 1.572-21.214; p=0.008 and OR: 4.888; 95% CI, 1.001-23.858; p=0.050, respectively).

Conclusion(s): This study enabled us to better characterize changes in gene expression and signaling pathways related to COVID-19 thrombosis. In this study we identified, characterized and validated miRNAs which could serve as novel, thrombosis-related biomarkers of the COVID-19, can be used for early stratification of patients and prediction of severity of infection development in an individual.